OptiOral Care.
Built on Science.
The Company
OptiOral Care is the dental division of Atumnus Life Sciences — an applied AI and longevity IP company co-founded by Daniel Nowak (Chief Technology Officer) and Daniel William Dorsey (Chief Executive Officer). Incorporated to bring published bioregulator peptide science to the dental profession without a prescription barrier.
Intellectual Property
Proprietary novel Ac-X-NH₂ peptide bioregulator analogs protected across multiple provisional patent applications. Patent pending across compositions of matter, formulation, and method-of-use domains. The compounds are non-injectable and outside the scope of expired prior art on injectable forms.
The Research Foundation
All formulas are built on published peer-reviewed research. Primary references include Khavinson et al., Molecules 2020 (AEDG in human gingival mesenchymal stem cells, p16/p21 reduction p<0.01); Sinjari et al., Stem Cell Rev. Reps. 2020 (AEDG in human periodontal ligament stem cells); and Pickart & Margolina, Int J Mol Sci 2018 (GHK: >4,000 human genes modulated). Over 800 publications from the Khavinson Institute underpin the bioregulator science.
Three doors.
One company.
Clinical & Wholesale
The Opti Series is dispensed through licensed dental practitioners. Wholesale, practice-direct, and clinical evaluation accounts are accepted on application.
Practitioner Inquiry →Editorial & Media
For press inquiries, interview requests, or editorial collaboration on bioregulator peptide research in dentistry, contact the OptiOral Care communications desk.
Press Inquiry →Strategic Inquiries
Atumnus is open to qualified strategic partners and investors aligned with the longevity and dental platform thesis. Data room access is provided on request.
Partner Inquiry →